Amgen 2011 Annual Report Download - page 177
Download and view the complete annual report
Please find page 177 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167 -
168 -
169 -
170 -
171 -
172 -
173 -
174 -
175 -
176 -
177 -
178 -
179 -
180 -
181 -
182 -
183 -
184
 |
 |
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Revenues
Revenues were as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):
2011 2010 2009
Product sales:
Neulasta®—U.S.................................................. $ 3,006 $ 2,654 $ 2,527
NEUPOGEN®—U.S. ............................................. 959 932 901
Neulasta®— International .......................................... 946 904 828
NEUPOGEN®— International ...................................... 301 354 387
ENBREL — U.S. ................................................. 3,458 3,304 3,283
ENBREL — Canada .............................................. 243 230 210
Aranesp®—U.S. ................................................. 986 1,103 1,251
Aranesp®— International .......................................... 1,317 1,383 1,401
EPOGEN®—U.S................................................. 2,040 2,524 2,569
Sensipar®—U.S.................................................. 518 459 429
Sensipar®(Mimpara®) — International ................................ 290 255 222
Vectibix®—U.S.................................................. 122 115 97
Vectibix®— International .......................................... 200 173 136
Nplate®—U.S. .................................................. 163 129 78
Nplate®— International ........................................... 134 100 32
Prolia®—U.S. ................................................... 130 26 —
Prolia®— International ............................................ 73 7 —
XGEVA®—U.S.................................................. 343 8 —
XGEVA®— International .......................................... 8 — —
Other — International ............................................. 58 — —
Total product sales .............................................. 15,295 14,660 14,351
Other revenues ..................................................... 287 393 291
Total revenues ................................................. $15,582 $15,053 $14,642
Geographic information
Outside the United States, we sell products principally in Europe and Canada. The geographic classification
of product sales was based upon the location of the customer. The geographic classification of all other revenues
was based upon the domicile of the entity from which the revenues were earned.
Certain geographical information with respect to revenues and long-lived assets (consisting of property,
plant and equipment) was as follows (in millions):
Years ended December 31,
2011 2010 2009
Revenues:
United States .................................................... $11,985 $11,636 $11,421
International countries ............................................. 3,597 3,417 3,221
Total revenues ................................................. $15,582 $15,053 $14,642
F-53